“…Unlike HCV, which elicits antibodies to several viral proteins during viraemia that usually persist throughout infection (Baumert et al , 2000), GBV-C/HGV antibodies are not generally detected during viraemia, although some studies have reported the detection of anti-GBV-C/HGV peptide reactivity (Fernandez-Vidal et al , 2007; Gomara et al , 2010; Pilot-Matias et al , 1996b; Schwarze-Zander et al , 2006; Tan et al , 1999; Van der Bij et al , 2005; Xiang et al , 1998). Following clearance of GBV-C/HGV viraemia, most individuals develop conformation-dependent antibodies to the envelope glycoprotein E2, and thus E2 antibody serves as a marker of prior infection (Barnes et al , 2007; Gutierrez et al , 1997; McLinden et al , 2006; Nakatsuji et al , 1992; Pilot-Matias et al , 1996a; Tacke et al , 1997; Tanaka et al , 1998).…”